A look at the breast cancer data for 3 rising early stage compounds
When the future of ADCs and bispecifics collide
How some novel combos may be ones to watch out for
On shiny lures and rose tinted glasses blinding reality
A busy and long weekend of data at ESMO24!
Which early stage onco developments are breathing fire and setting the room alike?
As regimens become more complex, so too do other implications
For all the breathless hype and attention focused on antibody-drug conjugates (ADCs) of late, you might…
On biomarkers, acquired resistance and immune escape, oh my!
7 early stage developments to watch out for at ESMO24
What can we learn from the initial LBA abstract titles?
Not all ADC paths are paved with gold
There's a fine line between success and failure in early stage iO
The good, the bad and the ughly from ESMO24
A detailed look through the window at ESMO24
